1. Pink Sheet
  2. >>Legislation
  3. >>Elections

Rx Industry Reassessing Political Donations In Wake Of Riots; Shift Towards Democrats Already Underway

 
• By Derrick Gingery

Donation patterns in 2020 campaign suggest rethinking may have taken place before the mob attacked the Capitol, potentially an assessment of the election prospects or because of Trump’s policies during his term.

House of Representatives debate second impeachment of Donald Trump
House members debate the second impeachment of President Trump. • Source: Screenshot

Three pharma industry trade associations are reassessing their political donation policies in the wake of the riots in the US Capitol, although trends suggest a shift was already underway towards Democrats.

More from Elections

‘A Lot Of That, It’s Meant To Start A Conversation’: How To Work With Trump

 
• By Alaric DeArment and Jessica Merrill

Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.

Bracing For RFK At HHS: Vaccine Safety Commission Likely First Step

 
• By Michael McCaughan

Robert F. Kennedy Jr. will become HHS secretary while retaining his anti-vaccine positions. His first action likely will be creating a new safety commission, which industry must hope holds off more drastic action.

Trump And Tariffs Top Generic Industry Concerns

 
• By Dave Wallace

At a lively AAM Access! conference in Florida, AAM President and CEO John Murphy acknowledged the negative effects of potential tariffs, but also suggested that the second Trump Administration could be an opportunity for the generics and biosimilars sectors to advance market reforms.

Pink Sheet Podcast: Kennedy’s Assurances To Gain HHS Nod, US FDA Coms Freeze Continues Thawing

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss what pushed a crucial Senate Finance Committee swing vote to support Robert F. Kennedy Jr. as HHS Secretary and the FDA slowly expanding its communications with the public amid the Trump Administration freeze.

More from Legislation

GOP Hill Staffer Joins US FDA As Senior Advisor, But Competing With MAHA For Legislative Position

 
• By Sarah Karlin-Smith

Industry likely wants Grace Graham to take the FDA’s top policy and legislative role, but she may be passed over for someone more tied to HHS Secretary Robert F. Kennedy Jr.’s interests.

Germany: Standardized Clauses In Clinical Trial Agreements Bring Opportunities But Also Tougher Negotiations

 
• By Francesca Bruce

Trial sponsors in Germany should start preparing negotiation strategies to tackle difficult discussions with trial sites over standardized clauses.

EU’s Critical Medicines Act: A Major Milestone Or Too Weak?

 
• By Neena Brizmohun

Newly proposed legislation for bolstering the EU’s drug manufacturing capacity and reducing its overreliance on foreign manufacturers includes a number of measures, such a requirement for EU countries to prioritize the security of supply over price when procuring drugs.